Business Description
Immutep Limited is an Australian biotechnology company founded in 1987 and headquartered in Sydney, focused on creating new treatments for cancer and autoimmune diseases by targeting a protein called LAG-3, which plays a key role in regulating the immune system. Its most advanced therapy, eftilagimod alfa, is being tested across a broad range of cancers, with several clinical trials currently underway covering conditions such as lung cancer, breast cancer, head and neck cancer, and others at various stages of development. The company also has early-stage programs targeting autoimmune diseases, and works alongside major partners including Merck & Co., Novartis, EOC Pharma, and Labcorp. Formerly known as Prima BioMed Ltd, the company rebranded as Immutep in November 2017.
